MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

Is Gilead's GH31 Acquisition a Game-Changer for Its Oncology Pipeline

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Gilead's Oncology and Inflammation Wave: Why the Market is Underpricing Diversification

1 week ago

Has Pfizer's Seagen Acquisition Reshaped the Oncology Landscape

2 months ago

Is Herbalife's Bioniq Acquisition a Game-Changer for its Personalized Nutrition Strategy

3 months ago

Is Brookfield's $1.2 Billion World Freight Acquisition a Game Changer

2 months ago

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Genmab/AbbVie's Phase 3 EPCORE DLBCL-4 lymphoma trial met its main goal, potentially expanding the market opportunity for their therapy.

GMAB

Stock News•1 months ago

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences awaits Gilead's HSV development plan while advancing ABI-6250 into multiple liver indications, per CEO Jason Okazaki at a Jefferies event.

ASMB

Stock News•2 months ago

Gilead's Transition Into A Long-Duration Biotech Platform

Gilead Sciences shares rose 34% as the company transitioned into a diversified therapeutic platform. HIV revenue grew 10% YoY, bolstered by Yeztugo’s $1B guidance, while oncology revenue climbed 37% Y...

GILD

Stock News•2 months ago

There's a Revolution in Cancer. But Can Big Pharma Afford It?

Revolution Medicines shares surged following positive developments for its pancreatic-cancer drug candidate. Despite market speculation, a near-term acquisition appears unlikely, suggesting investors ...

RVMD